Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy - Scorecard - MDSpire
Clinical Scorecard: Assessing Temporal Changes in Retinal Non-Perfusion Using Ultra-Widefield Fluorescein Angiography After Intravitreal Therapy for Diabetic Retinopathy
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients aged 18 years or older with type 1 or 2 diabetes mellitus, including those with varying stages of diabetic retinopathy.
Care Setting
Key Highlights
Ultra-widefield fluorescein angiography captures 82% of the retinal surface area, improving detection of peripheral lesions.
Guideline-Based Recommendations
Diagnosis
Management
First-line treatment for center-involving diabetic macular edema includes intravitreal anti-VEGF agents.
Consider individualized treatment plans based on the stage of diabetic retinopathy.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Fixed dosing of anti-VEGF may be necessary to sustain improvements in DR severity; monitor for side effects such as intraocular pressure changes.
Clinical Best Practices
Employ UWF FA for comprehensive assessment of peripheral retinal areas.
Consider combination therapy with anti-VEGF and pan-retinal photocoagulation for PDR.
Educate patients on treatment options and expected outcomes.
A nationwide Swedish cohort found a higher relative risk of anterior ischemic optic neuropathy among GLP-1 receptor agonist users, but the overall risks were low.
"AI could help reduce the burden on ophthalmology services by triaging large numbers of patients with diabetes and allowing specialists to focus on those who most urgently need care."
